WRBC
OBIO icon

W.R. Berkley Corp’s Orchestra BioMed OBIO Stock Holding History

W.R. Berkley Corp’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,902
Closed -$199K – 245
2022
Q4 		$199K Hold
19,902
– – 0.01% 330
2022
Q3 		$197K Sell
19,902
-472,310
-96% -$4.68M 0.01% 494
2022
Q2 		$4.9M Buy
492,212
+183,363
+59% +$1.82M 0.24% 69
2022
Q1 		$3.06M Buy
308,849
+200,000
+184% +$1.98M 0.16% 129
2021
Q4 		$1.1M Hold
108,849
– – 0.06% 327
2021
Q3 		$1.08M Buy
108,849
+98,910
+995% +$976K 0.07% 234
2021
Q2 		$101K Hold
9,939
– – 0.01% 369
2021
Q1 		$111K Hold
9,939
– – 0.01% 321
2020
Q4 		$127K Hold
9,939
– – 0.02% 164
2020
Q3 		$109K Buy
+9,939
New +$112K 0.02% 120

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFG
SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

W.R. Berkley Corp's OBIO Position: Q1 2023 in Review

W.R. Berkley Corp sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 19,902 shares — an estimated $199K sold.

W.R. Berkley Corp first reported a position in OBIO in Q3 2020 and held it in 10 quarters. The position peaked at $4.9M in Q2 2022. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

  • W.R. Berkley Corp reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
  • W.R. Berkley Corp sold 19,902 Orchestra BioMed shares in Q1 2023, an estimated $199K.
  • W.R. Berkley Corp first reported a position in Orchestra BioMed in Q3 2020 and held it in 10 quarters.
  • W.R. Berkley Corp's Orchestra BioMed position peaked at $4.9M in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on W.R. Berkley Corp's 13F filing for Q1 2023, filed 15 May 2023.